Macular edema results from fluid accumulation in the macular region of
the retina. Macular edema arises from various etiologies such as diabetes, AMD,
and RVO. Macular edema disrupts the central vision due to swelling of the
macula. Currently, the treatment plan involves the use of surgical and laser therapies
as well as drugs such as anti-VEGF therapies and NSAIDs. Surgery and laser
therapy are intended to prevent further damage to vision. However, anti-VEGF
therapies have been reported to improve the vision loss associated with macular
edema.
Analysts forecast the Global Macular Edema
market will grow at a CAGR of 9.1 percent over the period
2014-2018.
The Report recognizes the following companies as the key players in the
Global Macular Edema Market : Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG,
Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan
Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen
Pharmaceutical Co. Ltd.
NICE issues and updates technology appraisals and clinical guidelines to
recommend appropriate and effective treatments for different diseases. It plays
a role in increasing drug sales. In January 2013, NICE recommended Lucentis for
the treatment of DME. This recommendation superseded the November 2011
guidance, which concluded that recommending Lucentis was not effective
utilization of NHS resources. Lucentis has also been recommended for the
treatment of vision impairment as a result of macular edema associated with
RVO.
Covered in this
Report
This report covers the present scenario and the growth prospects of the
Global Macular Edema market for the period 2013-2018. To calculate the market
size, the report considers revenue generated through the sales of various drugs
administered to treat macular edema associated with distinct etiologies.
The report also presents the vendor landscape and a corresponding
detailed analysis of the top vendors in the Global Macular Edema market. In
addition, it discusses the major drivers that influence the growth of the
market. It also outlines the challenges faced by the vendors and the market at
large, as well as the key trends that are emerging in the market.
Global Macular Edema Market 2014-2018, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report covers
the Americas and the EMEA and APAC regions; it also covers the Global Macular
Edema market landscape and its growth prospects in the coming years. The report
also includes a discussion of the key vendors operating in this market.
According to the report, the Global Macular Edema market is driven by
several factors, of which the increase in the patient population is one of the
major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory
conditions such as uveitis, and RVO cause macular edema. The increase in the
incidence and prevalence of ophthalmological conditions such as AMD and DR is
expected to increase the patient population with macular edema during the
forecast period.
Further, the report states that although the Global Macular Edema market
has several drivers, the growth of the market is curtailed by some serious
challenges. One of the main challenges is increased use of off-label drugs. Use
of off-label drugs increases the market competition for approved branded drugs.
Some of the off-label drugs for the treatment of macular edema are bevacizumab,
topical NSAIDs, and drugs such as acetazolamide.
